AthleticsMD Clinical DeskSchedule an evaluation

AthleticsMD Clinical Desk

Trending

What other publishers are reporting on our subjects, summarised in our own words with a link to each original story. Summaries are written with AI and checked automatically against the story before they appear.

In the news

AA: Pulmonary aspiration, regurgitation under anesthesia more likely with GLP-1 RAs

Medical Xpress, carrying a HealthDay report, covers a UK national prospective observational cohort study in Anaesthesia of 47,039 adults at 119 sites undergoing anesthesia. Of these, 2.9% reported taking GLP-1 receptor agonists. Pulmonary aspiration and/or regurgitation occurred in 1.41% of that group versus 0.12% of others (odds ratio, 11.39), most often during emergence from anesthesia. Perioperative management varied, and the authors call for further prospective studies.

Why it matters: Relevant to adults using GLP-1 medicines who are considering surgery, and to the anesthesiologists, surgeons and referring clinicians involved in their perioperative care.

medicalxpress.com · October 4, 2026

Our summary →
In the news

Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial

ScienceAlert reports on a phase 3 trial in The New England Journal of Medicine of retatrutide, an experimental weekly injection, in 2,339 adults with obesity but without diabetes. At 12 milligrams, average weight loss was 25 percent after 80 weeks versus 3.9 percent with placebo; knee pain and sleep apnea events also fell more. Nausea was common. Eli Lilly funded the study, which did not compare it with existing drugs.

Why it matters: Relevant to Maryland adults with obesity but without diabetes who are exploring medical weight loss, including those with knee osteoarthritis or sleep apnea, and to clinicians who refer them.

yahoo.com · October 4, 2026

Our summary →
In the news

Menopause is a major health milestone, yet health records barely track it—new research

Medical Xpress republishes a piece from The Conversation by researchers who, in an observational review, examined electronic health records of almost 240,000 women in the NIH's All of Us Research Program. Only 12% of records mentioned menopause, though more than half the women reported the transition in surveys. Age at menopause and symptoms were also largely missing. The team is developing a short check-in questionnaire for patients.

Why it matters: Relevant to women in midlife and to referring clinicians who document reproductive health details in patients' electronic health records.

medicalxpress.com · October 4, 2026

Our summary →
In the news

'Perimenopause cost me my job and family life'

BBC reports, via Yahoo, one woman's personal account: Sally Williams spent almost 11 months in hospital across eight admissions during three years of deteriorating mental health, lost her finance job and was separated from her teenage son. Doctors initially thought she had depression; she later self-diagnosed perimenopause and credits HRT, while noting it may not suit everyone. She will speak at Worcester's Meno Fest on 7 October.

Why it matters: Relevant to Maryland adults approaching midlife who are weighing preventive or hormonal care, and to clinicians who see patients with mood changes in those years.

yahoo.com · October 4, 2026

Our summary →
In the news

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

CNBC reports that Eli Lilly and Novo are developing amylin-targeting obesity drugs to complement GLP-1 medicines. In a relatively small Phase 2 trial in patients with obesity and Type 2 diabetes, the highest-dose combination of Lilly's experimental eloralintide with tirzepatide produced 23.3% average weight loss at 48 weeks versus 14.8% on high-dose tirzepatide alone, though 10.8% to 27% stopped due to side effects. Phase 3 trials are needed.

Why it matters: Relevant to Maryland adults living with obesity and Type 2 diabetes who follow medical weight loss research, and to the clinicians who refer them for metabolic care.

cnbc.com · October 4, 2026

Our summary →
In the news

GLP-1 drugs like Ozempic linked to alarming side effect on nails

Newsweek reports on a cross-sectional, self-reported study presented at EADV in Vienna comparing 575 GLP-1 receptor users with 1,329 people with Type 2 diabetes who had never taken the drugs. Nail detachment was reported by 39 percent of users versus 9 percent of controls, and hair loss by 50 percent of users. Associations weakened after adjusting for skin conditions and nutritional deficiencies; authors say causation cannot be inferred.

Why it matters: Relevant to Maryland adults using or considering GLP-1 medications for weight loss or diabetes, and to clinicians who prescribe them or see patients with nail or hair concerns.

newsweek.com · October 4, 2026

Our summary →
In the news

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

News-Medical reports on a retrospective, real-world study of 122 adults with overweight or obesity, without type 2 diabetes, treated at two centers in Palermo, Italy. Alongside diet and activity advice, 24 weeks of tirzepatide was associated with fat mass falling 35.4% while skeletal muscle mass stayed stable. There was no control arm, and most participants were women.

Why it matters: Relevant to Maryland adults weighing medical weight loss, and to clinicians who refer them, interested in body-composition data from real-world tirzepatide care.

news-medical.net · October 4, 2026

Our summary →
In the news

Women are turning to testosterone, but what does the science actually say?

Medical Xpress republishes a Conversation explainer by Daniel Kelly on women's growing use of testosterone. A 2019 meta-analysis of 36 randomized trials supports it for distressing low sexual desire after menopause, the only evidence-backed use. An observational UK study of 510 women reported mood and cognitive improvements but cannot show causation. Long-term safety data remain limited, and the US has no approved female product.

Why it matters: Relevant to postmenopausal women in Maryland weighing menopause care options and to the gynecologists and primary care clinicians who discuss hormone therapy with them.

medicalxpress.com · October 4, 2026

Our summary →
In the news

GLP-1 use associated with nail detachment, hair loss

Healio reports on a congress presentation of an observational study comparing 575 GLP-1 receptor agonist users with 1,329 non-users, all with type 2 diabetes and/or obesity. Users reported more nail disorders and hair loss, including nail detachment (39.3% vs. 8.7%) and new-onset hair loss (26.1% vs. 11.6%). Researchers say the design cannot establish that the drugs caused the changes; a prospective study is planned.

Why it matters: Relevant to adults with type 2 diabetes or obesity who use or are considering GLP-1 medicines, and to the clinicians and dermatologists involved in their care.

healio.com · October 3, 2026

Our summary →
In the news

New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells

Medical Xpress reports EASD meeting data on CBL-514, an experimental injection meant to make fat cells self-destruct. In a small phase 2 MRI subgroup, CBL-514 (n=23) versus placebo (n=17), with participants of BMI 22–30 kg/m2, visceral fat was 10.45% lower than baseline versus 11.76% higher on placebo. A developer scientist co-authored it. Less weight regain after stopping tirzepatide was seen only in rats; phase 3 is recruiting.

Why it matters: Relevant to Maryland adults weighing nonsurgical abdominal fat-reduction options and to clinicians who manage medical weight loss or refer patients for body contouring.

medicalxpress.com · October 3, 2026

Our summary →
In the news

Even one strength training session a week could make a difference

In a commentary republished by ScienceDaily from The Conversation, Newcastle University researcher Christopher Hurst argues that strength training is central to countering sarcopenia, the age-related loss of muscle mass and strength. He cites evidence that a single weekly session may bring meaningful strength gains, particularly for newcomers. He adds that lighter weights lifted for 20 to 25 repetitions can match heavier loads when effort is high.

Why it matters: Relevant to older adults concerned about age-related muscle loss, mobility or falls, and to the rehabilitation and primary care clinicians who refer them.

sciencedaily.com · October 3, 2026

Our summary →
In the news

Foundayo noninferior to insulin glargine for CV outcomes

Healio reports on ACHIEVE-4, a Lilly-funded trial in which 2,749 patients with type 2 diabetes, overweight or obesity and established cardiovascular or kidney disease received oral orforglipron (Foundayo) or insulin glargine. At a median 2 years, major cardiovascular events occurred in 4.2% versus 5%, meeting noninferiority. The trial was not powered for superiority. Hypoglycemia was less common with orforglipron, while GI adverse events were more common.

Why it matters: Relevant to Maryland adults with type 2 diabetes, excess weight and cardiovascular or kidney disease, and to the endocrinology and cardiology clinicians who care for them.

healio.com · October 3, 2026

Our summary →
In the news

Survodutide induces ‘impressive’ weight loss in type 2 diabetes

Healio reports results from the phase 3 SYNCHRONIZE-2 trial of survodutide, a once-weekly injectable GLP-1/glucagon dual agonist, in 752 adults with type 2 diabetes and overweight or obesity. At 76 weeks, weight fell 8.2% and 9.8% on the 3.6 mg and 6 mg doses versus 3.9% with placebo. Gastrointestinal side effects were common and led some participants to stop treatment. The trial was funded by Boehringer Ingelheim.

Why it matters: Relevant to Maryland adults with type 2 diabetes and overweight or obesity exploring medical weight loss, and to the clinicians who refer them.

healio.com · October 3, 2026

Our summary →
In the news

Combining eloralintide with tirzepatide increases weight loss

Healio reports phase 2 trial data, presented at the European Association for the Study of Diabetes meeting, in 367 adults with type 2 diabetes and overweight or obesity. Over 48 weeks, the investigational amylin agonist eloralintide plus tirzepatide produced weight loss of up to 23.3%, versus 14.8% with tirzepatide 15 mg alone. Gastrointestinal side effects were most common. The Lilly-funded trial precedes a planned phase 3 study.

Why it matters: Relevant to Maryland adults with type 2 diabetes and overweight or obesity exploring medical weight loss, and to clinicians who refer them for metabolic care.

healio.com · October 3, 2026

Our summary →

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.

Schedule an evaluation →